| Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression CD May, N Sphyris, KW Evans, SJ Werden, W Guo, SA Mani Breast Cancer Research 13, 1-10, 2011 | 405 | 2011 |
| Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer KE Torres, V Ravi, K Kin, M Yi, BA Guadagnolo, CD May, BK Arun, ... Annals of surgical oncology 20, 1267-1274, 2013 | 153 | 2013 |
| Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models CD Lowery, M Dowless, M Renschler, W Blosser, AB VanWye, ... Clinical Cancer Research 25 (7), 2278-2289, 2019 | 70 | 2019 |
| The checkpoint kinase 1 inhibitor prexasertib induces regression of preclinical models of human neuroblastoma CD Lowery, AB VanWye, M Dowless, W Blosser, BL Falcon, J Stewart, ... Clinical Cancer Research 23 (15), 4354-4363, 2017 | 67 | 2017 |
| Radiation-associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions SP Dineen, CL Roland, R Feig, C May, S Zhou, E Demicco, GA Sannaa, ... Annals of surgical oncology 22, 3913-3920, 2015 | 67 | 2015 |
| Abemaciclib is active in preclinical models of ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling M Dowless, CD Lowery, T Shackleford, M Renschler, J Stephens, R Flack, ... Clinical Cancer Research 24 (23), 6028-6039, 2018 | 55 | 2018 |
| Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management M Gaebler, A Silvestri, J Haybaeck, P Reichardt, CD Lowery, LF Stancato, ... Frontiers in Oncology 7, 203, 2017 | 42 | 2017 |
| Olaratumab exerts antitumor activity in preclinical models of pediatric bone and soft tissue tumors through inhibition of platelet-derived growth factor receptor α CD Lowery, W Blosser, M Dowless, S Knoche, J Stephens, H Li, ... Clinical Cancer Research 24 (4), 847-857, 2018 | 38 | 2018 |
| Clinical observations and molecular variables of primary vascular leiomyosarcoma CL Roland, GM Boland, EG Demicco, K Lusby, D Ingram, CD May, ... JAMA surgery 151 (4), 347-354, 2016 | 35 | 2016 |
| Analysis of clinical and molecular factors impacting oncologic outcomes in undifferentiated pleomorphic sarcoma CL Roland, CD May, KL Watson, GA Al Sannaa, SP Dineen, R Feig, ... Annals of surgical oncology 23, 2220-2228, 2016 | 32 | 2016 |
| AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas CD May, J Garnett, XY Ma, SM Landers, DR Ingram, EG Demicco, ... BMC cancer 15, 1-12, 2015 | 31 | 2015 |
| MAGE-A3 is a clinically relevant target in undifferentiated pleomorphic sarcoma/myxofibrosarcoma AP Conley, WL Wang, JA Livingston, V Ravi, JW Tsai, A Ali, DR Ingram, ... Cancers 11 (5), 677, 2019 | 25 | 2019 |
| Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma CD May, SM Landers, S Bolshakov, XY Ma, DR Ingram, CM Kivlin, ... Cancer biology & therapy 18 (10), 816-826, 2017 | 23 | 2017 |
| Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy CD Lowery, W Blosser, M Dowless, M Renschler, LV Perez, J Stephens, ... Oncotarget 10 (53), 5523, 2019 | 20 | 2019 |
| A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib WD Blosser, JA Dempsey, AM McNulty, X Rao, PJ Ebert, CD Lowery, ... Oncotarget 11 (3), 216, 2020 | 15 | 2020 |
| Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor CM Kivlin, KL Watson, GA Al Sannaa, R Belousov, DR Ingram, KL Huang, ... Cancer Biology & Therapy 17 (2), 129-138, 2016 | 14 | 2016 |
| The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma KLJ Bill, J Garnett, X Ma, CD May, S Bolshakov, AJ Lazar, DC Lev, ... Laboratory investigation 95 (8), 951-961, 2015 | 14 | 2015 |
| Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers NA Schubert, CD Lowery, G Bergthold, J Koster, TF Eleveld, A Rodriguez, ... European Journal of Cancer 130, 168-181, 2020 | 11 | 2020 |
| Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas EJ Song, KA Ashcraft, CD Lowery, YM Mowery, L Luo, Y Ma, ... EBioMedicine 40, 224-230, 2019 | 8 | 2019 |
| Primary vascular leiomyosarcoma: clinical observations and molecular variables CL Roland, GM Boland, EG Demicco, K Lusby, D Ingram, CD May, ... JAMA surgery 151 (4), 347, 2016 | 5 | 2016 |
Kelsey L Schertz (Watson)University of Minnesota, Department of MedicineVerified email at umn.edu
